Substance / Medication

Enasidenib

Overview

Active Ingredient
enasidenib
RxNorm CUI
1940332

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Trial of Enasidenib Maintenance Post-Allogeneic Hematopoietic Cell Transplantation in Patients with IDH2-Mutated Acute Myeloid Leukemia.
Salhotra Amandeep, Bejanyan Nelli, Yang Dongyun et al. · Transplant Cell Ther · 2026
PMID: 40976487Observational
Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.
Jiménez-Vicente Carlos, Beneit Paola, Cano-Ferri Isabel et al. · Ann Hematol · 2025
PMID: 40650712ObservationalFull text (PMC)
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome.
DiNardo Courtney D, Venugopal Sangeetha, Lachowiez Curtis et al. · Blood Adv · 2023
PMID: 35973199ObservationalFull text (PMC)
Validated LC-MS/MS Method for Simultaneous Quantitation of Enasidenib and its Active Metabolite, AGI-16903 in Small Volume Mice Plasma: Application to a Pharmacokinetic Study.
Dittakavi Sreekanth, Hallur Gurulingappa, Purra Buchi Reddy et al. · Drug Res (Stuttg) · 2020
PMID: 31652462Observational
Cutaneous manifestations in D-2-hydroxyglutaric aciduria type 2 and response to enasidenib therapy.
Roux Jennifer, Brody Gabrielle, Metz Brandie et al. · JAAD Case Rep · 2025
PMID: 39839460Case ReportFull text (PMC)
Enasidenib-induced hepatitis in an individual with Type II D2-hydroxyglutaric aciduria.
Gold Jessica I, Stefanatos Arianna K, Fraser Jamie L et al. · JIMD Rep · 2024
PMID: 38736636Case ReportFull text (PMC)
Differentiation Syndrome in a Patient With NSCLC HarboringMutation Treated With Enasidenib: Case Report.
Sukhadia Bhoomika, Tan Dean, Oh Youjin et al. · JTO Clin Res Rep · 2024
PMID: 39346744Case ReportFull text (PMC)
Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation.
Geoerger Birgit, Schiff Manuel, Penard-Lacronique Virginie et al. · Nat Med · 2023
PMID: 37248298Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Enasidenib (substance)
SNOMED CT
763038001
UMLS CUI
C4519428
RxNorm CUI
1940332

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.